Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.60 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.60 |
| ▸ | ANPEP | P15144 | 2/20 | 0.60 |
| ▸ | MMP3 | P08254 | 4/20 | 0.54 |
| ▸ | MMP13 | P45452 | 4/20 | 0.54 |
| ▸ | MMP2 | P08253 | 4/20 | 0.54 |
| ▸ | MMP1 | P03956 | 3/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | MMP12 | P39900 | 2/20 | 0.54 |
| ▸ | LAP3 | P28838 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134279 | 0.92 | MMP13 (0.60) | ERAP2ERAP1ANPEPMMP3MMP13 | |
| SCHEMBL5053042 | 0.87 | ANPEP (0.61) | ERAP2ERAP1ANPEPMMP3MMP13 | |
| SCHEMBL5057989 | 0.86 | ERAP2 (0.62) | ERAP2ERAP1ANPEPLAP3 | |
| SCHEMBL1374357 | 0.84 | GRM3 (0.59) | — | |
| SCHEMBL7613692 | 0.82 | MMP3 (0.47) | MMP3MMP13MMP2MMP1MMP8 | |
| SCHEMBL7608852 | 0.80 | MMP13 (0.49) | MMP3MMP13MMP2MMP1MMP8 | |
| SCHEMBL5051262 | 0.80 | MMP13 (0.49) | MMP3MMP13MMP2MMP1MMP8 | |
| SCHEMBL5051270 | 0.79 | MMP1 (0.59) | MMP3MMP13MMP2MMP1MMP8 | |
| SCHEMBL1373664 | 0.79 | GRM3 (0.65) | — | |
| SCHEMBL7395511 | 0.79 | MMP2 (0.56) | ERAP2ERAP1ANPEPMMP3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | ERAP2 288/4885ERAP1 163/4885ANPEP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.